Skip to main content
Back
Watch Compare

Barinthus Biotherapeutics plc.

Data quality: 100%
BRNS
Nasdaq Manufacturing Chemicals
$0.55
▼ $0.04 (-6.65%)
Mkt Cap: 22.47 M
Price
$0.55
Mkt Cap
22.47 M
Day Range
$0.55 — $0.56
52-Week Range
$0.51 — $2.92
Volume
9,793
Open $0.56
50D / 200D Avg
$0.63
12.99% below
50D / 200D Avg
$0.96
42.99% below

Quick Summary

Key Takeaways

Negative free cash flow of -48.02 M

Growth

Revenue Growth (5Y)
N/A
Revenue (1Y)-100.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Quality

Return on Equity
-71.11%
Below sector avg (-53.41%)
ROIC-51.79%
Net MarginN/A
Op. MarginN/A

Safety

Debt / Equity
N/A
Current Ratio8.04
Interest Coverage-1383.43

Valuation

PE (TTM)
-0.34
Above sector avg (-1.48)
P/B Ratio0.27
EV/EBITDAN/A
Dividend YieldN/A

Price History

Financial Trends

Peer Comparison

vs Manufacturing sector median (1364 peers)
Metric Stock Sector Median
P/E -0.3 -1.5
P/B 0.3 1.6
ROE % -71.1 -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) -100.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -66.43 M
ROE -71.11% ROA -55.64%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -48.02 M
ROIC -51.79% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.04
Interest Coverage -1383.43 Asset Turnover 0.00
Working Capital 75.98 M Tangible Book Value 69.56 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.34 Forward P/E N/A
P/B Ratio 0.27 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -213.72%
Market Cap 22.47 M Enterprise Value -51.81 M
Per Share
EPS (Diluted TTM) -1.64 Revenue / Share 0.00
FCF / Share -1.18 OCF / Share -1.17
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 72.28%
SBC-Adj. FCF -48.93 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0.0 14.97 M 802,000.0 44.70 M 268,000.0
Net Income -66.43 M -61.07 M -73.35 M 5.34 M -50.87 M
EPS (Diluted) -1.64 -1.55 -1.91 0.14 -1.96
Gross Profit — — — — —
Operating Income -70.56 M -67.97 M -83.91 M -4.04 M -45.22 M
EBITDA — — — — —
R&D Expenses 25.56 M 42.24 M 44.87 M 42.35 M 20.37 M
SG&A Expenses — — — — —
D&A 5.85 M 5.80 M 5.43 M 4.32 M 602,000.0
Interest Expense 51,000.0 53,000.0 28,000.0 19,000.0 2.67 M
Income Tax -175,000.0 -44,000.0 -3.08 M -4.47 M -28,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 98.17 M 160.33 M 214.51 M 270.21 M 280.72 M
Total Liabilities 23.88 M 30.19 M 27.51 M 27.00 M 28.15 M
Shareholders' Equity 74.21 M 130.03 M 186.78 M 242.90 M 252.56 M
Total Debt — — — — —
Cash & Equivalents 70.46 M 110.66 M 142.09 M 194.39 M 214.05 M
Current Assets 77.79 M 125.74 M 156.91 M 213.04 M 226.77 M
Current Liabilities 10.02 M 15.66 M 12.60 M 12.24 M 11.16 M